Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Acute Lung Injury Market Grown from 2024 to 2025?

Over the past few years, the acute lung injury market size has seen steady growth, rising from $2.48 billion in 2024 to an estimated $2.60 billion in 2025. This implies a compounded annual growth rate (CAGR) of 4.7%. Factors contributing to this growth during the historic period include awareness campaigns, a surge in ICU admissions, smoking and air pollution issues, prevalence of hospital-acquired infections, and initiatives to reduce mortality rates.

What Growth Rate Is Anticipated for the Acute Lung Injury Market in the Coming Years?

The market size for acute lung injury is projected to experience consistent growth in the coming years. It is predicted to reach $3.09 billion by 2029, with a compound annual growth rate (CAGR) of 4.4%. This growth during the projected period could be ascribed to factors such as advancements in biologics and gene therapies, government-sponsored funding and grants, precision medicine evolution, stem cell and regenerative therapies, and worldwide health policy reforms. The prediction period is expected to see significant trends including the development of biologic drugs, wearable and remote tracking devices, inhalation-based treatments, CRISPR, gene editing technologies, and biosensors for real-time analysis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20704&type=smp

Who Are the Leading Companies in the Acute Lung Injury Market?

Major companies operating in the acute lung injury market are Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Medtronic plc, Baxter International Inc., Ono Pharmaceutical Co Ltd., Aster DM Healthcare, Octapharma AG, Cartesian Therapeutics Inc., Vapotherm Inc., Stemedica Cell Technologies Inc., Implicit Bioscience Ltd., Apeiron Biologics AG, Faron Pharmaceuticals Ltd., Histocell Sociedad Limitada, Vasomune Therapeutics Inc, Windtree Therapeutics Inc., Qx Therapeutics Inc., Asklepion Pharmaceuticals LLC, ReAlta Life Sciences Inc., MediciNova Inc.

What Are the Key Drivers of the Acute Lung Injury Market?

The acute lung injury market is poised for growth, fueled by the increasing incidence of respiratory ailments. These diseases—which primarily impact the lungs and other parts of the respiratory system—can lead to breathing difficulties and compromised lung function. The surge in these diseases can be attributed to factors such as heightened air pollution, smoking, a lack of physical activity, an aging populace and viral infections. Conditions like pneumonia, a type of respiratory disease, can cause acute lung injury by initiating intense inflammation and damaging the alveoli. This leads to compromised gas exchange and respiratory distress. To site a specific instance, as per the Australian Bureau of Statistics, a governmental agency based in Australia, there was a significant rise of about 33.54% in the death rate from influenza and pneumonia, going from 31.9 in 2021 to 42.6 per 100,000 people in 2022. Consequently, the increasing incidence of respiratory diseases is propelling the growth of the acute lung injury market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20704&type=smp

What Are the Key Market Segments in the Acute Lung Injury Industry?

The acute lung injury market covered in this report is segmented –

1) By Injury Type: Direct Injury, Indirect Injury

2) By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Other Therapies

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Direct Injury: Trauma-Induced Acute Lung Injury, Aspiration Pneumonitis, Pneumonia-Related Acute Lung Injury, Inhalation Injury

2) By Indirect Injury: Sepsis-Related Acute Lung Injury, Shock-Induced Acute Lung Injury, Acute Lung Injury Due To Blood Transfusion, Acute Lung Injury Associated With Pancreatitis

What Are the Latest Trends in the Acute Lung Injury Market?

Leading corporations within the acute lung injury market are honing their focus on the innovation of unique solutions such as peptide treatments as a way of solidifying their position. The peptide treatment is a process that involves the administration of short amino acid sequences, scientifically referred to as peptides, aimed at curing certain health conditions. A case in point is the launch of Aviptadil in November 2022 by Zuventus Healthcare Ltd., a healthcare firm based in India, specifically designed to tackle acute respiratory distress syndrome (ARDS). This revolutionary treatment comes with multiple benefits: it possesses mighty vasodilatory attributes that outperform prostacyclin by 50 times; it encourages surfactant production by connecting to alveolar type II cells, which aids in lung preservation; it inhibits pro-inflammatory cytokines like IL-6 and TNF-alpha thanks to its anti-inflammatory properties; and it regulates immune response in the lungs due to its immunomodulatory action. Furthermore, Aviptadil has demonstrated clinical effectiveness in enhancing the prognosis for patients struggling with severe ARDS as a result of viral infection.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acute-lung-injury-global-market-report

What Are the Key Regional Markets in the Acute Lung Injury Industry?

North America was the largest region in the acute lung injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20704

This Report Delivers Insight On:

1. How big is the acute lung injury market, and how is it changing globally?

2. Who are the major companies in the acute lung injury market, and how are they performing?

3. What are the key opportunities and risks in the acute lung injury market right now?

4. Which products or customer segments are growing the most in the acute lung injury market?

5. What factors are helping or slowing down the growth of the acute lung injury market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model